Dermatology offices spend ~13 hours weekly on prior authorizations, file ~39 requests per physician annually, and see roughly one-third denied, creating operational costs and delayed initiation of ...

As the number of actionable biomarkers in thoracic oncology continues to grow, the role of the multidisciplinary care team evolves to ensure patients receive comprehensive biomarker testing and ...

Dry eye is a multifactorial disease characterized by a loss of homeostasis of the tear film layer, which can present itself in different ways. Dry Eye Awareness Month is dedicated ...

Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal. Patients with stage 2 and ...

Use of automated insulin delivery technology improves a Healthcare Effectiveness Data and Information Set quality measure in ...

Workforce expansion authorized after the 2024 Harlem outbreak remains incomplete, with 35 staff onboard versus a planned 56, leaving gaps in inspection and response throughput. A second lethal cluster ...

Linvoseltamab-gcpt is now a preferred treatment for multiple myeloma after 4 prior therapies, joining other bispecific antibodies in the NCCN guidelines. The FDA granted accelerated approval to ...

FDA approved zidesamtinib for previously treated ROS1+ locally advanced/metastatic NSCLC, marking GSK’s entry into approved lung cancer therapeutics following acquisition of Nuvalent’s portfolio. ROS1 ...

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, and ...

Mean LDL-C at 6 months was 76.3 vs 85.6 mg/dL, yielding an adjusted difference of −6.62 mg/dL and higher attainment of LDL-C <50 mg/dL. Intervention uptake increased intensive and combination ...

US prevalence includes 16.5 million adults and >10% of children; ~40% of adults have moderate-to-severe disease, with many inadequately controlled and underreporting symptoms. Patient hesitancy ...

A multiyear “tariff cliff” sets 0% through July 2028, then 100% for one year and 200% thereafter, explicitly tying penalties to failure to establish US manufacturing capacity. Sparse implementation ...